A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Dutasteride (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms REDUCE
- Sponsors GlaxoSmithKline; GSK
- 12 Sep 2021 Results of post-hoc analysis of REDUCE in 3060 asymptomatic men with baseline IPSS less than 8 and in 2198 symptomatic men with baseline IPSS greater than equal to 8 not taking alpha-blockers or 5 alpha-reductase inhibitors, published in the Journal of Urology.
- 20 Oct 2020 Results (n=889) from a retrospective analyses published in the Journal of Urology
- 03 Sep 2019 Results assessing association between statin use and prostate volume (PV) change over time using data from this trial, published in the BJU International